Amenorrhea (Therapy)

Wyeth-Ayerst Introduces Treatment for Absence of Menstruation

Published in Women's Health Weekly, August 18th, 1997

Wyeth-Ayerst Laboratories, a division of American Home Products Corporation, announced clearance from the U.S. Food and Drug Administration (FDA) to market Crinone 4%, natural progesterone in a bioadhesive gel.

Scheduled to become available in late 1997, the gel is indicated for treatment of secondary amenorrhea, the absence of the monthly menstrual cycle in reproductive age women who have experienced regular cycles in the past. Previously, the higher dosage strength of Crinone 8% gel received marketing clearance for use in conjunction with infertility treatment.

Common factors that may contribute to secondary amenorrhea include weight loss, regular...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1997-08-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry